Australia's decision-making framework is dominated by a single-payer that exercises its extraordinary power through HTA. Managing the reality of this power asymmetry is critical for the proponents of change.
Power asymmetry is the biggest issue for advocates of HTA reform
October 28, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
‘Trojan Horse’ treatment offers hope for Australians facing relapsed multiple myeloma
November 24, 2025 - - Latest News -
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - - Latest News -
A scrapped website, almost $100 million, and the politics of what really matters
November 23, 2025 - - Latest News -
Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD
November 22, 2025 - - Australian Biotech -
Syntara launches Phase 2 trial aiming to teduce transfusion burden in myelodysplastic syndromes
November 22, 2025 - -
Alterity Therapeutics chairman reflects on two decades of progress as company enters new era
November 22, 2025 - - BioPharma -
Treasurer blocks US takeover of Mayne Pharma on national interest grounds
November 22, 2025 - - Latest News
